作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy
-
摘要: Castleman病是纳入我国《第一批罕见病目录》的罕见血液系统疾病，该病临床异质性强，分为多种亚型。其中，特发性多中心型Castleman病(idiopathic multicentric Castleman disease，iMCD)病情重、预后差，是临床医师面临的重大挑战。白细胞介素(interleukin，IL)-6靶向药物(如司妥昔单抗)是国内外多个指南、共识推荐治疗iMCD的首选药物，2022年7月司妥昔单抗在国内上市，标志着我国针对iMCD的IL-6靶向治疗时代的开启。IL-6靶间治疗已在国内陆续展开，本文阐述过去20年间(IL-6靶向治疗前时代)中国Castleman病的诊疗现状，以及国内研究者在该领域取得的研究成果。
-
关键词:
- Castleman病 /
- 罕见病 /
- 临床研究
Abstract: Castleman disease (CD) is a group of rare and heterogenous hematological diseases included in the 'Rare disease catalogue' of China. Among the different clinical subtypes of CD, idiopathic multicentric Castleman disease (iMCD) is characterized by symptomatic inflammatory symptoms with poor prognosis. Interleukin-6 (IL-6) targeted therapy (eg. siltuximab) is now considered as the most important treatment option according to international and domestic treatment guidelines and consensus. On July 2022, siltuximab became available in Chinese market, heralding the era of IL-6 targeted therapy in China. Thus, it is a good time point to review the state-of-the-art technology in the field of diagnosis and treatment of CD. We also highlight some of the clinical investigations conducted by Chinese researchers.-
Key words:
- Castleman disease /
- rare disease /
- clinical research
作者贡献：张路负责文献复习和论文初稿撰写；李剑负责论文审阅及修改。利益冲突：所有作者均声明不存在利益冲突 -
[1] Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9: 822-830. doi: 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4 [2] Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. doi: 10.1016/j.lanwpc.2023.100720 [3] van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132: 2115-2124. [4] Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129: 1646-1657. doi: 10.1182/blood-2016-10-746933 [5] 中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42: 529-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK202107001.htm [6] Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5: 122-128. doi: 10.1182/bloodadvances.2020003607 [7] Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol, 2018, 97: 1641-1647. doi: 10.1007/s00277-018-3347-0 [8] Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133: 1720-1728. doi: 10.1182/blood-2018-11-884577 [9] Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33: 1035-1038. doi: 10.1038/s41375-018-0323-6 [10] Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study[J]. Oncologist, 2020, 25: 963-973. doi: 10.1634/theoncologist.2019-0986 [11] Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation[J]. Chest, 2023. doi: 10.1016/j.chest.2023.03.022. [12] Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141: 2654-2657. [13] Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34: 100747. doi: 10.1016/j.lanwpc.2023.100747 -
下载:
点击查看大图
图(1)
计量
- 文章访问数: 224
- HTML全文浏览量: 67
- PDF下载量: 70
- 被引次数: 0
